SOURCE: Cardiovascular Sciences

March 25, 2008 08:10 ET

Cardiovascular Sciences, Inc. Reaches Operating Agreement With Medical Technologies Enterprises, Inc.

ORLANDO, FL--(Marketwire - March 25, 2008) - Cardiovascular Sciences, Inc. (PINKSHEETS: CVSC), a client company of the award-winning University of Central Florida Technology Incubator program, is enthused to announce that the company has reached an operating agreement with Med. Tech. Enterprises, Inc. Under this agreement, Cardiovascular Sciences, Inc. will immediately assume all daily operations of Med. Tech. Enterprises, Inc. Under this agreement, earnings will accrue to the benefit of Cardiovascular Sciences, Inc.

Cardiovascular Sciences, Inc. is already well underway in developing and producing a proprietary line of health-related products. Mr. Eric Edelmann, president of Med. Tech. Enterprises, stated, "With all the recent advances and impressive data that have become available on nutritionals, supplements and anti-oxidants, it is appropriate and even exciting to team up with a company like Cardiovascular Sciences to bring our own product line of quality and effective health products to market."

The Company's CEO, Dr. Larry Hooper, expressed, "This is a very positive step forward for Cardiovascular Sciences and its shareholders. At the same time, we will continue to develop our primary, post-surgical anti-adhesion technology which stands to propel Cardiovascular Sciences as a leading innovator in medical technology."

About Cardiovascular Sciences

Cardiovascular Sciences, Inc. is an advanced medical device company which is developing a novel technology platform to address the problem of post-surgical and post-traumatic adhesions. Adhesions and the complications of adhesions are a significant problem worldwide for a wide range of specialists, including general surgeons, cardiothoracic surgeons, orthopedic, plastic, and ophthalmologic and otolaryngology specialists to name just some of them. In addition, the veterinary field has a tremendous need for a product that can prevent similar problems in a wide variety of animals. The Company's unique materials and processes promise a more cost-effective and decidedly more efficient and capable means to deal with a problem that has been so devastating to so many. Current sponsored research at the University of Central Florida (UCF) and previously at other institutions indicate that The Company is on the right path and progressing well.

In addition to the anti-adhesion technology, The Company owns technology in a variety of other areas, including thrombo-resistant coatings, enhanced intra-arterial balloon pumping catheters, cell engineered vascular tissues, and a method for improved recovery of the heart following cardioplegia. This yields a diversified portfolio with projects in various stages of development.

Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.

Contact Information

  • For more information contact:
    Cardiovascular Sciences Investor Relations